[1]
|
Zhang, S., Sun, K., Zheng, R., et al. (2021) Cancer Incidence and Mortality in China, 2015. Journal of the National Cancer Center, 1, 2-11. https://doi.org/10.1016/j.jncc.2020.12.001
|
[2]
|
Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications, 42, 937-970. https://doi.org/10.1002/cac2.12359
|
[3]
|
Hoy, H., Lynch, T. and Beck, M. (2019) Surgical Treatment of Lung Can-cer. Critical Care Nursing Clinics of North America, 31, 303-313. https://doi.org/10.1016/j.cnc.2019.05.002
|
[4]
|
Jones, G.S. and Baldwin, D.R. (2018) Recent Advances in the Management of Lung Cancer. Clinical Medicine Journal, 18, s41-s46. https://doi.org/10.7861/clinmedicine.18-2-s41
|
[5]
|
Felip, E., Altorki, N., Zhou, C., et al. (. 2021) Adjuvant Ate-zolizumab after Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer [IMpower010]: A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet, 398, 1344-1357. https://doi.org/10.1016/S0140-6736(21)02098-5
|
[6]
|
Langer, C.J., Gadgeel, S.M., Borghaei, H., et al. (2016) Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Can-cer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. The Lancet Oncology, 17, 1497-1508. https://doi.org/10.1016/S1470-2045(16)30498-3
|
[7]
|
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., et al. (2018) Pembroli-Zumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 2078-2092.
https://doi.org/10.1056/NEJMoa1801005
|
[8]
|
Yan, N., Huang, S., Li, L., et al. (2022) Case Report: Durable Re-sponse to Immuno-Chemotherapy in a Case of ROS1 Fusion-Positive Advanced Lung Adenocarcinoma: A Case Report. Frontiers in Pharmacology, 13, Article 898623.
https://doi.org/10.3389/fphar.2022.898623
|
[9]
|
Chen, M., Xu, Y., Zhao, J., et al. (2023) Comparison of Chemo-therapy plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 24, 278-286.
https://doi.org/10.1016/j.cllc.2022.12.003
|
[10]
|
Carbone, D.P., Reck, M., Paz-Ares, L., et al. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. New England Journal of Medicine, 376, 2415-2426. https://doi.org/10.1056/NEJMoa1613493
|
[11]
|
Darrason, M., Chatelain, E., Ranchon, F., et al. (2020) Do Systemic Treatments Delivered after Nivolumab Result in Better Outcomes? A Bicentric Case-Control Study. Respiratory Medicine and Research, 77, 100-105.
https://doi.org/10.1016/j.resmer.2020.02.001
|
[12]
|
Brahmer, J.R., Lee, J.S., Ciuleanu, T.E., et al. (2023) Five-Year Survival Outcomes with Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. https://doi.org/10.1200/JCO.22.01503
|
[13]
|
Paz-Ares, L., Ciuleanu, T.E., Cobo, M., et al. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. https://doi.org/10.1016/S1470-2045(20)30641-0
|
[14]
|
Paz-Ares, L.G., Ciuleanu, T.E., Pluzanski, A., et al. (2023) Safety of First-Line Nivolumab plus Ipilimumab in Patients with Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of Thoracic Oncology, 18, 79-92. https://doi.org/10.1016/j.jtho.2022.08.014
|
[15]
|
Xu, N., Ying, K., Wang, Z., et al. (2019) Phase Ib Study of Sintili-mab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 37, e20546.
https://doi.org/10.1200/JCO.2019.37.15_suppl.e20546
|
[16]
|
Yang, Y., Wang, Z.., Fang, J., et al. (2020) Efficacy and Safety of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT An-ti-PD-1-11). Journal of Thoracic Oncology, 15, 1636-1646.
https://doi.org/10.1016/j.jtho.2020.07.014
|
[17]
|
Jiang, H., Zheng, Y., Qian, J., et al. (2021) Efficacy and Safety of Sintilimab in Combination with Chemotherapy in Previously Untreated Advanced or Metastatic Nonsquamous or Squa-mous NSCLC: Two Cohorts of an Open-Label, Phase 1b Study. Cancer Immunology, Immunotherapy, 70, 857-868. https://doi.org/10.1007/s00262-020-02738-x
|
[18]
|
Molife, C., Brnabic, A., Stefaniak, V.J., et al. (2023) Sintilimab plus Chemotherapy for First-Line Treatment of Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Network Meta-Analysis. Immunotherapy, 15, 293-309. https://doi.org/10.2217/imt-2022-0252
|
[19]
|
Lee, A. and Keam, S.J. (2020) Tislelizumab: First Approval. Drugs, 80, 617-624.
https://doi.org/10.1007/s40265-020-01286-z
|
[20]
|
Dahan, R., Sega, E., Engelhardt, J., et al. (2015) FcγRs Modulate the Anti-Tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell, 28, 285-295. https://doi.org/10.1016/j.ccell.2015.08.004
|
[21]
|
Shen, L., Guo, J., Zhang, Q., et al. (2020) Tislelizumab in Chinese Patients with Advanced Solid Tumors: An Open-Label, Non-Comparative, Phase 1/2 Study. Journal for ImmunoThera-py of Cancer, 8, e000437corr1.
https://doi.org/10.1136/jitc-2019-000437corr1
|
[22]
|
Wang, Z., Zhao, J., Ma, Z., Cui, J., et al. (2020) A Phase 2 Study of Tislelizumab in Combination with Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Lung Cancer, 147, 259-268. https://doi.org/10.1016/j.lungcan.2020.06.007
|
[23]
|
Lu, S., Wang, J., Yu, Y., et al. (2021) Tislelizumab plus Chemotherapy as First-Line Treatment for Locally Advanced or Meta-static Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 16, 1512-1522. https://doi.org/10.1016/j.jtho.2021.05.005
|
[24]
|
Wang, J., Lu, S., Yu, X., et al. (2021) Tislelizumab plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 7, 709-717. https://doi.org/10.1001/jamaoncol.2021.0366
|
[25]
|
Zhu, W., Geng, Q., Peng, H., et al. (2022) Efficacy and Safety of Low-Dose Nab-Paclitaxel plus Tislelizumab in Elderly Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 12, Article 802467. https://doi.org/10.3389/fonc.2022.802467
|
[26]
|
Lu, S., Yu, Y., Barnes, G., Qiu, X., et al. (2022) Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients with Nonsquamous Non-Small Cell Lung Cancer. The Cancer Journal, 28, 96-104. https://doi.org/10.1097/PPO.0000000000000583
|
[27]
|
Jiang, T., Wang, P., Zhang, J., et al. (2021) Toripalimab plus Chemotherapy as Second-Line Treatment in Previously EGFR-TKI Treated Patients with EGFR-Mutant-Advanced NSCLC: A Multicenter Phase-II Trial. Signal Transduction and Targeted Ther-apy, 6, Article No. 355. https://doi.org/10.1038/s41392-021-00751-9
|
[28]
|
Zhou, J., Zhou, F., Xie, H., et al. (2020) An Advanced Non-Small Cell Lung Cancer Patient with Epidermal Growth Factor Receptor Sensitizing Mutation Re-sponded to Toripalimab in Combination with Chemotherapy after Resistance to Osimertinib: A Case Report. Transla-tional Lung Cancer Research, 9, 354-359.
https://doi.org/10.21037/tlcr.2020.02.09
|
[29]
|
Wang, Z., Wu, L., Li, B., et al. (2023) Toripalimab plus Chemothera-py for Patients with Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). Journal of Clinical Oncology, 41, 651-663. https://doi.org/10.1200/JCO.22.00727
|
[30]
|
Zhou, C., Wang, Z., Sun, Y., et al. (2022) Sugemalimab Versus Placebo, in Combination with Platinum-Based Chemotherapy, as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (GEMSTONE-302): Interim and Final Analyses of a Double-Blind, Randomised, Phase 3 Clinical Trial. The Lancet Oncology, 23, 220-233.
https://doi.org/10.1016/S1470-2045(21)00650-1
|
[31]
|
Chen, P., Li, Y., Jing, X., et al. (2022) Cost-Effectiveness Analysis of Sugemalimab in Combination with Chemotherapy as First-Line Treatment in Chinese Patients with Metastatic NSCLC. Lung Cancer, 174, 157-164.
https://doi.org/10.1016/j.lungcan.2022.11.008
|
[32]
|
Pu, X., Wang, Q., Liu, L., et al. (2023) Rh-Endostatin plus Camrelizumab and Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. Cancer Medicine, 12, 7724-7733.
https://doi.org/10.1002/cam4.5526
|
[33]
|
Zhou, C., Chen, G., Huang, Y., et al. (2021Mar) Camrelizumab plus Car-boplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314.
https://doi.org/10.1016/S2213-2600(20)30365-9
|
[34]
|
Ren, S., Chen, J., Xu, X., et al. (2022) Camrelizumab plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, 17, 544-557.
https://doi.org/10.1016/j.jtho.2021.11.018
|
[35]
|
Lim, S.W. and Ahn, M.J. (2019) Current Status of Immune Checkpoint Inhibitors in Treatment of Non-Small Cell Lung Cancer. The Korean Journal of Internal Medicine, 34, 50-59. https://doi.org/10.3904/kjim.2018.179
|
[36]
|
Socinski, M.A., Nishio, M., et al. (2021) IMpower150 Final Overall Survival Analyses for Atezolizumab plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 16, 1909-1924. https://doi.org/10.1016/j.jtho.2021.07.009
|
[37]
|
West, H., McCleod, M., Hussein, M., et al. (2019) Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemo-therapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937. https://doi.org/10.1016/S1470-2045(19)30167-6
|
[38]
|
Shu, C.A., Gainor, J.F., Award, M.M., et al. (2020) Neoad-juvant Atezolizumab and Chemotherapy in Patients with Resectable Non-Small-Cell Lung Cancer: An Open-Label, Mul-ticentre, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 786-795. https://doi.org/10.1016/S1470-2045(20)30140-6
|
[39]
|
Ikeuchi, N., Igata, F., Kinoshita, E., et al. (2023) Real-World Efficacy and Safety of Atezolizumab plus Bevacizumab, Paclitaxel and Carboplatin for First-Line Treatment of Japanese Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer. Anticancer Research, 43, 713-724. https://doi.org/10.21873/anticanres.16210
|
[40]
|
Morgensztern, D., Dols, M.C., Ponce Aix, S., et al. (2021) Nab-Paclitaxel plus Durvalumab in Patients with Previously Treated Advanced Stage Non-Small Cell Lung Cancer (ABOUND.2L+). Frontiers in Oncology, 10, Article 569715. https://doi.org/10.3389/fonc.2020.569715
|
[41]
|
Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., et al. (2017) Durvalumab after Chemo-Radiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377, 1919-1929.
https://doi.org/10.1056/NEJMoa1709937
|
[42]
|
Spigel, D.R., Faivre-Finn, C., Gray, J.E., Vicente, D., et al. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311. https://doi.org/10.1200/JCO.21.01308
|
[43]
|
Borghetti, P., Imbrescia, J., Volpi, G., et al. (2022) Chemo-Radiotherapy plus Durvalumab for Loco-Regional Relapse of Resected NSCLC. Radiation Oncology, 17, Article No. 124. https://doi.org/10.1186/s13014-022-02084-5
|
[44]
|
Tanaka, H., Tanzawa, S., Misumi, T., et al. (2022) A Phase Ii Study of S-1 and Cisplatin with Concurrent Thoracic Radiotherapy Followed by Durvalumab for Unresectable, Locally Advanced Non-Small-Cell Lung Cancer in Japan (SAMURAI Study): Primary Analysis. Therapeutic Advances in Medical Oncology, 14.
https://doi.org/10.1177/17588359221142786
|
[45]
|
Paz-Ares, L., Ciuleanu, T.E., Cobo, M., et al. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. https://doi.org/10.1016/S1470-2045(20)30641-0
|
[46]
|
Paz-Ares, L.G., Ramalingam, S.S., Ciuleanu, T.E., et al. (2022) First-Line Nivolumab plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes from the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17, 289-308. https://doi.org/10.1016/j.jtho.2021.09.010
|
[47]
|
Meng, L.-F., Huang, J.-F., Luo, P.-H., Huang, S.-X. and Wang, H.-L. (2022) The Efficacy and Safety of Immune Checkpoint Inhibitor plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Investigational New Drugs, 40, 810-817. https://doi.org/10.1007/s10637-022-01232-8
|
[48]
|
Sumi, T., Sekikawa, M., Nagahisa, Y., et al. (2022) Relation of Overall Tumor Burden with Severe Immune-Related Adverse Events in Nivolumab plus Ipilimumab Treatment for Lung Cancer. Investigational New Drugs, 40, 1315-1321.
https://doi.org/10.1007/s10637-022-01305-8
|